BPC-157, a stable peptide derived from gastric juice, promotes wound healing in skin, gut, tendon, bone, nerve, and blood vessels through vessel regulation, clot management, and gene activation — with no reported toxicity in animal studies.
No toxicity (LD1 not achieved)In extensive animal testing, BPC-157 showed no reportable toxicity even at the highest doses tested — the dose that would kill 1% of animals (LD1) was never reached.
What the researchers found
BPC-157 promotes wound healing across virtually all tissue types through vessel regulation, clot management, and rapid gene expression activation, effective at both µg and ng doses via oral or injectable routes.
Why it matters
A single peptide that promotes healing across so many tissue types through common mechanisms could have wide therapeutic applications, from surgical recovery to chronic wound management.
The numbers in context
No reported toxicity; LD1 not achieved; effective at µg and ng doses; oral and injectable routes equipotent; heals skin, gut, tendon, ligament, muscle, bone, nerve, spinal cord, cornea, blood vessels
How the study worked
Comprehensive review of animal studies on BPC-157 wound healing, covering skin wounds, fistulas, burns, diabetic ulcers, and multiple internal tissue types.
Who was studied
Review of animal studies on BPC-157 wound healing across multiple tissue types
What this study cannot tell us
Based almost entirely on animal studies. Clinical trial data is limited to ulcerative colitis and multiple sclerosis. No large randomized controlled trials for wound healing in humans. Many studies come from the same research group.
How to read the evidence
This is a comprehensive review of primarily animal (rat) studies from a prolific but concentrated group of researchers. While BPC-157 has been used in human trials for ulcerative colitis and multiple sclerosis, no large randomized controlled trials for wound healing in humans have been conducted. The evidence is extensive but predominantly preclinical.
When this study was published
Published in 2021, this review summarizes decades of BPC-157 research. The peptide remains one of the most discussed experimental peptides in regenerative medicine, though clinical translation has been slow.
The bigger picture
BPC-157 occupies a unique position in peptide research — it has one of the most extensive preclinical evidence bases of any experimental peptide, spanning dozens of tissue types and injury models. However, nearly all research comes from a single laboratory group in Croatia, and the lack of independent replication and large human trials has limited mainstream acceptance. The peptide's multi-tissue healing capability through common mechanisms (vascular regulation, gene activation) makes it a fascinating case study in regenerative peptide biology.
Questions still open
- Why has BPC-157 not progressed to large-scale human clinical trials for wound healing despite decades of animal evidence?
- Would independent laboratory replication of these results strengthen the case for clinical development?
- Could BPC-157 be combined with standard wound care protocols to accelerate healing in diabetic ulcers or surgical recovery?
Common questions
What is BPC-157 and where does it come from?
Is BPC-157 approved for medical use?
Read the original research
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
Frontiers in pharmacology, 12, 627533
Citation
Seiwerth, Sven; Milavic, Marija; Vukojevic, Jaksa; Gojkovic, Slaven; Krezic, Ivan; Vuletic, Lovorka Batelja; Pavlov, Katarina Horvat; Petrovic, Andrea; Sikiric, Suncana; Vranes, Hrvoje; Prtoric, Andreja; Zizek, Helena; Durasin, Tajana; Dobric, Ivan; Staresinic, Mario; Strbe, Sanja; Knezevic, Mario; Sola, Marija; Kokot, Antonio; Sever, Marko; Lovric, Eva; Skrtic, Anita; Blagaic, Alenka Boban; Sikiric, Predrag. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.. Frontiers in pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533